Raiffeisen Bank International AG Sells 9,076 Shares of DexCom, Inc. $DXCM

Raiffeisen Bank International AG decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 37.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,223 shares of the medical device company’s stock after selling 9,076 shares during the quarter. Raiffeisen Bank International AG’s holdings in DexCom were worth $1,012,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Andra AP fonden bought a new position in shares of DexCom during the 2nd quarter valued at approximately $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom during the second quarter valued at approximately $26,000. SJS Investment Consulting Inc. boosted its position in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after purchasing an additional 384 shares during the period. Financial Consulate Inc. bought a new position in shares of DexCom in the third quarter worth approximately $29,000. Finally, Sound Income Strategies LLC increased its stake in shares of DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $73.08 on Monday. The stock has a 50 day moving average of $69.49 and a 200 day moving average of $69.26. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $91.87. The firm has a market cap of $28.13 billion, a PE ratio of 34.80, a PEG ratio of 1.42 and a beta of 1.49. The company has a current ratio of 1.88, a quick ratio of 1.59 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The company’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DXCM shares. Mizuho lifted their target price on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the company a “buy” rating in a research report on Friday, February 13th. Wells Fargo & Company dropped their price objective on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research note on Friday, February 13th. UBS Group decreased their target price on DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Finally, Citigroup restated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.18.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.